Health Plan Transparency Still At Issue, ICER Finds

In its third annual report on fair access to prescription drugs, the US pricing watchdog found high concordance with some of its recommended policies, but thinks greater transparency is needed for a thorough assessment.

Fair access
ICER finds payers are providing fair access to drugs, but data are limited • Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) is in its third year of reviewing fair access to prescription drugs, but continues to face obstacles to doing a thorough assessment. Greater transparency is needed to make a clearer evaluation of consumers’ access to the drugs they are prescribed, the report – which deemed only two of 18 drugs included to be fairly priced and eligible for cost-sharing analysis – concludes.

Key Takeaways

  • The Institute for Clinical and Economic Review says insurers and other payers are meeting much of its recommendations for fair access to drugs, but more information is needed for a thorough assessment.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip